


Pharmaceuticals & Biotechnology | Small Cap
Aarey Drugs & Pharmaceuticals Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency and profitability, indicating a solid financial foundation and efficient operations. However, growth metrics present a challenge, with declines in operating profit, EPS, asset growth, and net income. Liquidity is adequate, but there's room for improvement in managing short-term obligations. While the company shows good asset turnover and inventory management, collection periods for receivables are lengthy, impacting cash flow. Overall, Aarey Drugs & Pharmaceuticals showcases resilience but needs to address growth concerns to ensure long-term sustainability and competitiveness.
Aarey Drugs & Pharmaceuticals Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency and profitability, indicating a solid financial foundation and efficient operations. However, growth metrics present a challenge, with declines in operating profit, EPS, asset growth, and net income. Liquidity is adequate, but there's room for improvement in managing short-term obligations. While the company shows good asset turnover and inventory management, collection periods for receivables are lengthy, impacting cash flow. Overall, Aarey Drugs & Pharmaceuticals showcases resilience but needs to address growth concerns to ensure long-term sustainability and competitiveness.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
58.43
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
58.43
P/B RATIO
1.54
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
0.49
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
-5.52
EV/EBITDA RATIO
17.87
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹81.8 as on Aug 6, 2026.
The company's growth metrics present a mixed picture. While revenue growth is strong, there are declines in operating profit, earnings per share, asset growth, and net income. This suggests challenges in converting revenue growth into higher profits and efficient asset management. The company needs to address these areas to ensure sustainable growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 41.67 | -15.01 | -5.49 | 19.7 | -0.42 |
| Operating Profit Growth Rate | 120 | -27.27 | -50 | -25 | 133.33 |
| Earnings Per Share (EPS) Growth | -7.19 | -42.25 | 12.08 | -14.97 | -1.41 |
| Asset Growth Rate | 5.15 | 18.78 | 4.12 | -3.96 | 2.06 |
| Net Income Growth Rate | 0 | -42.86 | 25 | -20 | 0 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Par Drugs & Chemicals Ltd | 7.40 | 9.48 | Undervalued | 17.00 | 10.65 | 13.00 |
| 2 | Infinium Pharmachem Ltd | 6.42 | 26.92 | Neutral | 22.00 | 6.43 | 14.00 |
| 3 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 58.43 | Neutral | 7.00 | 1.40 | 4.00 |
| 4 | BPL Ltd | 5.46 | -30.53 | Neutral | -4.82 | -1.69 | -8.55 |
| 5 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 6 | Quest Laboratories Ltd | 5.27 | 9.84 | Neutral | 18.00 | 9.16 | 15.00 |
| 7 | Sotac Pharmaceuticals Ltd | 5.27 | 18.18 | Neutral | 18.00 | 4.45 | 6.00 |
| 8 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 9 | Krebs Biochemicals & Industries Ltd | 4.16 | -4.34 | Highly Undervalued | -4.00 | -7.85 | -4.00 |
| 10 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral